Streetbeat News

ONTX

Onconova Therapeutics Inc

https://www.onconova.com/

CEO

Steven Fruchtman

Employees

Industry

Pharmaceutical Preparation Manufacturing

onconova therapeutics, inc. (nasdaq: ontx) is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer. using a proprietary chemistry platform, onconova has created an extensive library of targeted anti-cancer agents designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells. onconova has three product candidates in clinical trials and six active pre-clinical programs. onconova seeks to develop products that improve the outcome for cancer patients by directly addressing the disease, its recurrence, and the burden of side-effects associated with current methods of treatment.

Open

1.00

Mkt cap

21M

Volume

1.3M

High

1.00

P/E Ratio

-1.04

52-wk high

1.45

Low

0.77

Div yield

N/A

52-wk low

0.55

Onconova Therapeutics has announced a definitive merger agreement to acquire all outstanding equity interests of Trawsfynydd. This move has led to a decrease in Onconova's share prices.

Portfolio Pulse from Benzinga Newsdesk

April 02, 2024 | 3:53 pm

Onconova Therapeutics, Inc. (ONTX) has completed an all-stock acquisition of Trawsfynydd Therapeutics, Inc., with a combined equity value of $132M. Additionally, Trawsfynydd will raise $14M through committed private placement financing.

Portfolio Pulse from Benzinga Newsdesk

April 02, 2024 | 11:13 am

In Thursday's after-market session, several healthcare stocks showed notable movements. Gainers included China Pharma Holding, SenesTech, Lucy Scientific Discovery, OneMedNet, Universe Pharmaceuticals, and Vaxxinity with increases ranging from 4.99% to 12.7%. Losers were led by Modular Medical, Adial Pharmaceuticals, Pacific Biosciences, Nuwellis, Perspective Therapeutics, and Onconova Therapeutics, with declines between 4.39% and 16.3%. Key financial updates were noted for Lucy Scientific Discovery, Modular Medical, and Pacific Biosciences.

Portfolio Pulse from Benzinga Insights

February 15, 2024 | 9:31 pm

Icosavax, Inc. (NASDAQ:ICVX) shares surged approximately 45% in pre-market trading following AstraZeneca's announcement of plans to acquire Icosavax for up to $1.1 billion. Icosavax also reported positive interim Phase 2 results for its IVX-A12 vaccine candidate. Other stocks experiencing pre-market movements include gainers Bruush Oral Care Inc. (BRSH), Connect Biopharma Holdings Limited (CNTB), and losers Harbor Custom Development, Inc. (HCDI), which filed for Chapter 11 bankruptcy, and Oracle Corporation (ORCL), which reported mixed quarterly results.

Portfolio Pulse from Avi Kapoor

December 12, 2023 | 1:00 pm

In Monday's after-market session, several healthcare stocks experienced significant movements. Connect Biopharma Hldgs (CNTB) saw a 51.1% increase, while IN8bio (INAB) rose by 14.84%, and Inotiv (NOTV) by 13.85% following their Q4 earnings release. OneMedNet (ONMD), AquaBounty Techs (AQB), and Cue Health (HLTH) also saw gains. Conversely, Assure Hldgs (IONM), Pasithea Therapeutics (KTTA), Lucy Scientific Discovery (LSDI), Onconova Therapeutics (ONTX), Exicure (XCUR), and NRX Pharmaceuticals (NRXP) experienced declines.

Portfolio Pulse from Benzinga Insights

December 11, 2023 | 9:31 pm

bluebird bio, Inc. (NASDAQ:BLUE) shares increased by 6.6% after presenting positive gene therapy data at the ASH Annual Meeting. Other stocks experienced significant movement in Monday's mid-day session, with notable gainers including Pasithea Therapeutics Corp. (NASDAQ:KTTA), NextPlay Technologies, Inc. (NASDAQ:NXTP), and MorphoSys AG (NASDAQ:MOR). The Cigna Group (NYSE:CI) shares rose after withdrawing from a merger with Humana Inc. (NYSE:HUM), and Macy's, Inc. (NYSE:M) increased on news of a buyout bid. Conversely, Near Intelligence, Inc. (NASDAQ:NIR) and Troika Media Group, Inc. (NASDAQ:TRKA) fell sharply due to bankruptcy filings, while Altamira Therapeutics Ltd. (NASDAQ:CYTO) dropped after announcing a reverse stock split. Cryptocurrency-related stocks like Marathon Digital Holdings, Inc. (NASDAQ:MARA) and Riot Platforms, Inc. (NASDAQ:RIOT) declined alongside a drop in Bitcoin's price.

Portfolio Pulse from Avi Kapoor

December 11, 2023 | 6:13 pm

In Monday's pre-market session, several healthcare stocks experienced significant movements. Pasithea Therapeutics (KTTA) saw a sharp rise of 86.6%, while Assure Holdings (IONM) and Poseida Therapeutics (PSTX) also saw substantial gains. On the downside, Cogent Biosciences (COGT) and X4 Pharmaceuticals (XFOR) faced notable declines. These movements reflect changes in investor sentiment and could be driven by recent company news, market trends, or broader sector shifts.

Portfolio Pulse from Benzinga Insights

December 11, 2023 | 1:06 pm

Green Giant Inc. (GGE) shares plummeted by 37.1% in pre-market trading due to a proposed public offering. Other stocks experienced significant movement in pre-market trading, with notable gainers including NextPlay Technologies (NXTP), Onconova Therapeutics (ONTX), and Macy's (M), which received a $5.8 billion acquisition bid. Losers included Near Intelligence (NIR), which filed for Chapter 11, and Cyngn Inc. (CYN), which announced a $5 million public offering.

Portfolio Pulse from Avi Kapoor

December 11, 2023 | 12:59 pm

In Friday's after-market session, several healthcare stocks experienced significant movements. Onconova Therapeutics (ONTX) saw a 42.5% increase, while Trinity Biotech (TRIB) faced an 18.2% decline. Other notable gainers include AcelRx Pharmaceuticals (ACRX), IGM Biosciences (IGMS), Applied Therapeutics (APLT), MeiraGTx Holdings (MGTX), and Geovax Labs (GOVX). Conversely, Milestone Scientific (MLSS), Gyre Therapeutics (GYRE), Oncternal Therapeutics (ONCT), Phio Pharmaceuticals (PHIO), and Blue Water Biotech (BWV) were among the losers.

Portfolio Pulse from Benzinga Insights

December 08, 2023 | 9:30 pm

Onconova Therapeutics (NASDAQ:ONTX) reported Q3 2023 earnings with an EPS of $(0.23), surpassing the $(0.29) estimate, marking a 20.69% beat and an 11.54% improvement from last year. However, sales of $57.00K fell short of the $70.00K estimate by 18.57%, mirroring last year's sales.

Portfolio Pulse from vinayak@benzinga.com

November 14, 2023 | 10:15 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.